ArticleAnnals of medicine2021
Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Article in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06078969 (The Efficacy of Oral Prednisone in Treating Langerhans Cell Histiocytosis of Bone in Childhood and Adolescence), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Oral Prednisone in Treating Langerhans Cell Histiocytosis of Bone in Childhood and Adolescence: A Multi-center, Open-label, Randomized-controlled, Phase II Study
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real-world study.International journal of cancer · 2026Article
- Survival outcomes and adverse prognostic factors of Langerhans cell histiocytosis: a 40-year experience from a single tertiary center in Thailand.Annals of hematology · 2026Article
- Application of pretreatmentAnnals of hematology · 2025Article
- Efficacy and safety of dabrafenib-targeted therapy for pediatric langerhans cell histiocytosis: a systematic review and meta-analysis.Translational pediatrics · 2025Article
- High CCR6 expression increases the risk of pediatric Langerhans cell histiocytosis.Blood science (Baltimore, Md.) · 2025Article
- Prednisone and Vincristine for the Treatment of Pediatric Rosai-Dorfman Disease: A Case Report.Case reports in medicine · 2025Article
- Beyond BRAFCancer medicine · 2024Article
- Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Journal of cancer research and clinical oncology · 2024Observational
- Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study.Frontiers in medicine · 2024Article
- Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Cell communication and signaling : CCS · 2022Review
- Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study.Orphanet journal of rare diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to understand the clinical characteristics and outcomes of children with Langerhans cell histiocytosis (LCH) in China.
methodsWe conducted a retrospective study of 95 paediatric patients with LCH in West China Second University Hospital of Sichuan University between July 2013 and August 2020.
resultsThe onset age of multisystem LCH (MS-LCH) patients with risk organ (RO) involvement was younger than that of MS-LCH without RO involvement (
conclusionsIn this study, LCH was a highly heterogeneous disease characterized molecularly by MAPK-pathway activating mutations. Vincristine, prednisone and cytarabine-based chemotherapy combined with vemurafenib improved the prognosis of childhood LCH. In future, prospective clinical trials and novel therapeutic strategies should be developed to improve outcomes in paediatric patients with LCH.KEY MESSAGEChildren with Langerhans cell histiocytosis in China present highly heterogeneous clinical characteristics, with up to 60% of cases harbouring mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.